Negative-pressure wound therapy (NPWT) is frequently employed in the treatment of complex wounds. The authors present a description of real-time streaming therapy of a variety of wound chemotherapeutic agents through NPWT. Doxycycline, which acts as a competitive inhibitor of matrix metalloproteinases and tumor necrosis factor alpha and further decreases inflammation through the reduction of nitrous oxide production, may prove helpful when delivered in this manner. To the authors’ knowledge, this is the first report in the literature describing this method of delivery of doxycycline.
Falanga V.Growth factors and chronic wounds: the need to understand the microenvironment . J Dermatol. 1992;19:667-672.
2.
Wolvos T.Wound instillation-the next step in negative pressure wound therapy: lessons learned from initial experiences. Ostomy Wound Manage. 2004;50:56-66.
3.
Baxter CRImmunologic reactions in chronic wounds. Am J Surg. 1994;167:12S-14S.
4.
Giovinco N.Wound chemotherapy by the use of negative pressure wound therapy and infusion . Eplasty. 2009;10(e9).
5.
Armstrong D. , Jude D.The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc. 2002;92:12-18.
6.
Lobmann R., Ambrosch A., Pittasch D., Waldmann K., Schieweck S., Lehnert H.Expression of MMP-8 and TIMP-2 in diabetic and non-diabetic wounds [abstract] . Diabetologica. 2000; 43(suppl 1):A15.
7.
Lobmann R., Ambrosch A., Schultz G., Waldmann K., Schiweck A., Lehnert H.Expression of gelatinase (MMP-2) in diabetic and non-diabetic wounds [abstract] . Diabetologica. 2001;44(suppl 1):A4.
8.
Lobmann R., Ambrosch A., Schultz G., Waldmann K., Schiweck S., Lehnert H.Expression of matrix metalloproteinases and their inhibitors in wounds of diabetic and non-diabetic patients. Diabetologica. 2002;45:1011-1016.
9.
Lobmann R., Schultz G., Lehnert H.Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications . Diabetes Care. 2005;28:461-471.
10.
Chin GA, Thigpin TG, Perrin KJ, Moldawer LL, Schultz GSTreatment of chronic ulcers in diabetic patients with a topical metalloproteinase inhibitor, doxycycline. Wounds. 2003;15:315-323.
11.
Lamperter S. , Slight S., Weber K.Doxycycline and tissue repair in rats. J Lab Clin Med. 2002;139:295-302.
12.
Armstrong DG , Lavery LANegative pressure wound after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704-1710.
13.
Stechmiller J., Cowan L., Schultz G.The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs . 2009;11:336-344.
